Head-to-head evidence
Clozapine vs Risperidone (Risvan)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Schizophrenia
Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline
Clozapine
Marketed by HLS Therapeutics Inc.
NCT00250575 · Phase 3 · completed
The study was open-label, single-arm, and had no placebo or active comparator; all 43 participants received clozapine. Its primary measures focused on hematological tests, blood-related adverse events, and monitoring-system compliance rather than a clinical symptom endpoint, and no results are posted.
Next expected readout: April 2027 · NCT04580134 (registry estimate)
Risperidone (Risvan)
Marketed by Laboratorios Farmacéuticos Rovi, S.A.
NCT03160521 · Phase 3 · completed
The study randomized 438 participants to two risperidone doses or placebo under triple masking, with 390 participants included in the reported primary efficacy analysis. The clinical primary endpoint was the change in PANSS total score, reported as -24.6 and -24.7 points with risperidone versus -11.0 with placebo, but statistical significance for this primary comparison is not stated, so the result remains unclear.
Next expected readout: December 2027 · NCT07047651 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Clozapine's landscape · Risperidone (Risvan)'s landscape